NCT03519464View on ClinicalTrials.gov

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
BIOLOGICAL

Gardasil 9

Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH